Viela Bio (VIE) Stock Price, News & Analysis

Company Overview

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Key Stats

• Today's Range: $53.01 to $53.01
• 50-Day Range: $52.92 to $53.20
• 52-Week Range: $25.02 to $65.00
• Volume: N/A
• Average Volume: 1.07 million shs
• Market Capitalization: $2.91 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VIE Stock Analysis - Frequently Asked Questions

How were Viela Bio's earnings last quarter?

Viela Bio, Inc. (NASDAQ:VIE) issued its earnings results on Sunday, February, 28th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.10. The firm earned $9.34 million during the quarter, compared to the consensus estimate of $5.10 million.

When did Viela Bio IPO?

Viela Bio (VIE) raised $150 million in an initial public offering on Thursday, October 3rd 2019. The company issued 7,500,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What other stocks do shareholders of Viela Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Viela Bio investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Toast (TOST), Ginkgo Bioworks (DNA), Globant (GLOB) and Saia (SAIA).

Company Calendar

• Last Earnings: 2/28/2021
• Today: 1/23/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:VIE
• CUSIP: N/A
• CIK: N/A
• Web: www.vielabio.com
• Phone: 240 558 0038
• Fax: N/A
• Employees: 166
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($7.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-86,430,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -33.97%
• Return on Assets: -31.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.51
• Quick Ratio: 19.49

Sales & Book Value

• Annual Sales: $50 million
• Price / Sales: 58.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.14 per share
• Price / Book: 7.42

Miscellaneous

• Outstanding Shares: 54,950,000
• Free Float: N/A
• Market Cap: $2.91 billion
• Optionable: Not Optionable
• Beta: 0.43